ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Keenova Therapeutics, ZARS Pharma and Grünenthal side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Keenova Therapeutics×ZARS Pharma×Grünenthal×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Keenova TherapeuticsZARS PharmaGrünenthal
studies on the registry2472493
open to participants now203
phase 3 studies under way200
reach primary completion within a year002
programswith a study of their own in two years1none read3

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseKeenova TherapeuticsZARS PharmaGrünenthal
Phase 100%–

Grünenthal: 1 of its 3 programs at phase 1

  1. GRT7041phase 1
33%
Phase 200%–

Grünenthal: 2 of its 3 programs at phase 2

  1. tegacoratphase 2
  2. Inosine Monophosphatephase 2
67%
Phase 300%–00%
Approved, new studies

Keenova Therapeutics: 1 of its 1 programs at approved, new studies

  1. Microbial Collagenaseapproved, new study
100%
–00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Keenova Therapeutics0 readouts · 0 phase 3············
ZARS Pharma0 readouts · 0 phase 3············
Grünenthal1 readouts · 0 phase 3··········

Grünenthal, Sep ’27: 1 program whose next study reaches primary completion

  1. Inosine Monophosphatephase 2 · Sep 0 · NCT07807644
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Keenova Therapeutics

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

ZARS Pharma

No programs read for this company.

Grünenthal

New programs 1

Reached a new phase 1

  • tegacoratphase 2 · Oct 27 · Muscular Dystrophy, Duchenne

Study stopped 0

None

Primary completion later 0

None

Where they overlap

No condition where two of them both have programs.

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Keenova Therapeutics 0 of 1 · ZARS Pharma 0 of 0 · Grünenthal 0 of 3 programs. Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.